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DockingTuberculosis (TB) is one of the oldest threats to public health. TB is caused by the pathogen
Mycobacterium tuberculosis (MTB). The Sigma factors are essential for the survival of MTB.
The Sigma factor Sigma F (SigF) regulates genes expression under stress conditions. The
SigF binds to RNA polymerase and forms a holoenzyme, which initiates the transcription
of various genes. The Usfx, an anti-SigF protein, binds to SigF and alters the transcription
initiation and gene expression. In the present work, virtual screening studies are taken up
to identify the interactions between SigF and small molecular inhibitors which can inhibit
the formation of holoenzyme. The studies reveal that ARG 104 and ARG 224 amino acid
residues of SigF protein are forming important binding interactions with the ligands. The
in silico ADME properties for the ligand data set are calculated to check the druggability
of the molecules.
 2015 Asian African Society for Mycobacteriology. Production and hosting by Elsevier Ltd.
All rights reserved.Introduction
The communicable disease tuberculosis (TB) is caused by the
oldest human pathogen Mycobacterium tuberculosis (MTB). In
the year 2013 nearly 1.5 million people died and 9.0 million
new TB cases were reported [1]. MTB can survive in the host
organism against the change in environmental conditions
due to complex gene expression, which is controlled by speci-
fic Sigma factors [2,3]. The Sigma factors, a regulatory family
of proteins, play a key role in the immunopathology of MTB[4,5]. The MTB encodes 13 Sigma factors, among which
Sigma factor F (SigF) protein regulates the SigB and SigC factor
protein expression, which are important in virulence [6–8].
The SigF is involved in direct and indirect regulation of many
genes, which are essential for cell wall protein synthesis and
survival of MTB in the host system [9,10]. Geiman et al.
reported that 187 genes in stationary phase and 277 genes
in late stationary phase show less expression in the SigF-
deficient MTB [11]. The Usfx, an anti-Sigma factor, negatively
regulates the activity of SigF, in response to a variety of
Table 1 – The structures and Hydrogen bonding interactions of Sigma lifechem databank ligand molecules with SigF protein, prioritized with best docking score and energy
are represented.
S. No Structure Glide score Glide energy Intermolecular interactions
M1
(2S)-4-{[4-(Dimethylamino)phenyl]amino}-2-(4-methyl-1-
piperazinyl)-4-oxobutanoic acid
9.39 40.90 ILE54:O–M1:H50
ARG104:HE–M1:O12
ARG104:HH21–M1:O12
ARG104:HH21–M1:O13
ARG224:HH22–M1:O19
M2
(2S)-4-[(2,4-Difluorophenyl)amino]-4-oxo-2-(1-
piperazinediiumyl)butanoate
9.32 38.46 ARG104:HE–M2:O12
ARG104:HH21–M2:N1
ARG104:HH21–M2:O12
ARG224:HH22–M2:O18
M3
(2S)-4-[(4-Isopropylphenyl)amino]-2-(4-methyl-1-piperazinyl)-
4-oxobutanoic acid
8.94 36.34 ARG224:HH22–M3:O12
ARG224:HH12–M3:O12
ARG104:HH21–M3:O18
ARG57:HH12–M3:O11
M4
(2R)-4-(2-Naphthylamino)-4-oxo-2-(1-piperazinediiumyl)
butanoate
8.52 44.35 ARG104:HH21–M4:O12
ARG104:HE–M4:O15
ARG57:HH12–M4:O11
GLU59:OE2–M4:H25
GLU59:OE1–M4:H25
Pi–cation
M4–ARG57:NH2
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M5
(2R)-4-[(2,4-Dimethylphenyl)amino]-2-(4-methyl-1-piperazinyl)-4-oxobutanoic acid
8.24 33.89 GLU59:OE1–M5:H24
GLU59:OE2–M5:H24
ALA55:O–M5:H40
ARG104:HE–M5:O11
ARG104:HH21–M5:O11
ARG224:HH22–M5:O16
Pi–cation
ARG224:NH1–M5
Pi–sigma
PHE225:HE2–M5
M6
N-[2-(Dimethylamino)-2-(2-thienyl)ethyl]-N 0-(3-nitrophenyl)ethanediamide
8.08 36.46 ARG224:HH22–M6:O16
ARG224:HH22–M6:N7
ARG224:HH12–M6:O16
ARG104:HH21–M6:O19
ASP174:OD1–M6:H43
Pi–cation
ARG104:NH1–M6
ARG104:NH2–M6
The 12,000 molecules of Sigma lifechem database is used for screening process. The screening process carried out with HTVS, SP and XP docking modes, the output of 68 molecules are analyzed. The
6 molecules (M1 to M6) with the best docking score are represented with docking interactions in the table.
Table 2 – ADME properties.
C1 C2 C3 C4 C5 C6 C7 C8 C9 C10 C11 C12 C13 C14 C15 C16 C17
Mol Stars CNS Mol Weight SASA Volume DHB AHB QPlogP o/w QPP Caco QPlog BB Meta Human OralA % Human OralA N and O Rule of 5 Rule of 3
M1 1 0 334.417 636.73 1116.938 2 9.5 0.769 12.671 0.148 6 2 42.182 7 0 1
M2 0 0 313.303 538.80 935.71 3 8 1.087 9.197 0.097 3 2 37.828 6 0 1
M3 0 0 333.43 664.67 1154.632 2 8.5 0.273 9.156 0.351 5 2 42.558 6 0 1
M4 0 1 327.382 615.62 1057.566 3 8 0.754 5.476 0.479 3 2 35.747 6 0 1
M5 0 0 319.403 626.1 1088.01 2 8.5 0.545 14.135 0.039 6 2 44.339 6 0 1
M6 0 2 362.403 590.23 1049.348 2 6.5 1.687 59.566 1.14 4 3 68.591 8 0 0
Optimum values for the parameter considered. 95% of available drugs fall in the range of stars (more number of stars indicate that the molecule is less drug like) [Stars]: 0–5, predicted central nervous
system activity [CNS]: 2(inactive) + 2(active), molecular weight [Mol Weight]: (130–725), solvent accessible surface area using a probe with 1.4 A˚ radius [SASA]: 300.0–1000.0, total solvent accessible
volume in cubic angstroms [Volume]: 500.0–2000.0, hydrogen bond donors [DHB]: (0.0–6.0), hydrogen bond acceptors [AHB]: (2.0–20.0), predicted octanol/water partition coefficient [QPlogP o/w]: (2.0–
6.5), Predicted apparent Caco-2 cell (model for gut blood barrier) permeability in nm/s [QPP Caco]: <25 poor, >500 great, predicted brain/blood barrier partition coefficient [QPlogBB]: (3.0–1.2), number
of likely metabolic reactions [Meta]: (1–8), human oral absorption [Human OralA]: 1 low, 2 medium, 3 high, % human oral absorption [% Human OralA]: >80% high, <25% low, number of nitrogens and
oxygens [N and O]: 2–15, [Rule of 5] (4), [Rule of 3] (3). C = Column.
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Fig. 1 – Binding interaction poses of ligands with SigF protein for the best docked molecules. The ligand molecules are
represented in red ball and stick model, p–p stacking are shown in orange color, intermolecular Hydrogen Bonds are
represented in black and the SigF protein is shown in light blue color.
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the in silico screening has been taken up to identify small
molecules, which can act as antagonists for the SigF protein.
Methodology
The SigF protein binds to its cognate anti-SigF (Usfx) in its reg-
ulatory circuit; in the absence of Usfx, SigF initiates transcrip-
tion initiation and gene expression, which leads to protein
synthesis and in turn helps in the survival of MTB. Finding
inhibitors for the SigF protein at the Usfx binding site will
arrest the survival of MTB. In the present work in silico screen-
ing is taken up to identify competitive inhibitors for Usfx.
Virtual screening
The structure of SigF was considered from an earlier work
[13]. The SigF structure was energy minimized using the pro-
tein preparation wizard in Maestro 9.0.111 (Maestro v 9.0.111
Schrodinger LLC, New York, NY) applying OPLS 2001 (opti-
mized potential for liquid simulations 2001) force field with
default parameters [14]. The Virtual screening work flow of
Schrodinger involves three consecutive steps: (a) receptor grid
generation; (b) ligand preparation; and (c) Glide ligand dock-
ing [15]. The grid was generated using the Gridgen module
of Schrodinger Suite at the active site amino acid residues
[13,16]. The Sigma lifechem small molecule database was
considered and retrieved in Sdf file format. The ligands were
subjected to ligand preparation using the Ligprep 2.5 module
of Schrodinger Suit [17] and during the process, tautomeric
states and ionization states were generated using the epic
module. The work flow utilizes the Glide module for Ligandand Receptor docking. Glide filters the molecules using
HTVS (high throughput virtual screening), SP (standard preci-
sion) and XP (extra precision) modes [16]. The OPLS 2001 force
field [14,18] parameters were applied while performing dock-
ing calculations. The molecules with the best Glide score and
Glide energy were visually inspected and considered for fur-
ther analysis. The SASA (solvent accessible surface area) for
the receptor and ligand complexes were calculated with the
default parameters. The receptor–ligand complexeswere ana-
lyzed using Accelrys Discovery Studio Visualizer (Accelrys
Software Inc., 2007 Accelrys Discovery Studio Visualiser v
2.5.5. Accelrys Software Inc., San Diego).
ADME properties
The Absorption Distribution Metabolism and Elimination
(ADME) properties were calculated using the QikProp [18]
module of Schrodinger suite (QikProp, version 3.0,
Schrodinger, LLC, New York, NY, 2010) for assessing the drug-
gability and to filter the ligand molecules at an early stage of
identifying the new antagonists.
Results and discussion
Virtual screening
The virtual screening studies are carried out with 12,000 small
ligand molecules from the Sigma lifechem database. In the
process, the grid box is generated with 75 · 75 · 75 A˚3 around
the active site amino acids which were considered from an
earlier study [13]. In the ligand preparation process using
the epic program, 5 stereo isomers from 32 structures
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Fig. 2 – Solvent accessible surface area of SigF protein and the SigF protein–ligand complexes for the best docked molecules.
The solvent accessible surface area (SASA) of SigF protein before docking (SigF BD) is represented in blue color line and the
protein–ligand complex is represented with maroon color line for the best docked molecules. The amino acid numbers are
represented on X-axis and SASA values are shown on Y-axis.
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membered rings with the least energy are considered;
20,646 molecular structures are generated in the ligandpreparation output file, which are used in the screening pro-
cess. Among the 20,646 ligand molecules, 6790 molecules
are docked in HTVS mode; the top 10% (679 of 6790) of the
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Fig 2. (continued)
I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 4 ( 2 0 1 5 ) 3 3 0 –3 3 6 335ligand molecules from the HTVS screening process are con-
sidered for SP docking. The 679 ligand molecules are docked
and the top 10% of SP docked molecules are utilized for XP
docking mode. Finally, 68 docked complexes are generated
in the XP flexible docking mode. The docked complexes are
analyzed, visually inspected and the data of a sample of 6
molecules (M1 to M6) with the corresponding docking proper-
ties generated namely docking score, docking energy, docking
interactions and ADME properties, are presented in Tables 1
and 2. The hydrogen bond interactions and p cation interac-
tions are depicted in Fig. 1. The virtual screening analysisreveals that the amino acid residues ILE54, ARG57, GLU59,
ARG104, ASP174 and ARG224 are involved in the hydrogen
bond formation and p cation interactions with the M1 to M6
ligand molecules. The amide group oxygen in M6 molecule
and the amide group oxygen in M1 to M5 molecules bound
in the docked complex through hydrogen bonds with the
amine hydrogen of ARG104 in SigF protein. The piperazine-
1-yl acetic acid moiety present in the M1 to M5 molecules is
consistently binding to the ARG224 amino acid of the SigF
protein. The carboxyl oxygen forms a hydrogen bond with
the amino group (hydrogen) of the ARG224. The docking result
336 I n t e r n a t i o n a l J o u r n a l o f M y c o b a c t e r i o l o g y 4 ( 2 0 1 5 ) 3 3 0 –3 3 6analysis reveals the common presence of piperazine-l-yl acetic
acid moiety and an amide group in all the ligands and is cap-
able of binding effectively with ARG104 and ARG224 of the
SigF protein. The SASA calculations are carried out for the
SigF protein and the SigF–Ligand docked complexes and are
represented in Fig. 2. The SASA values of the SigF protein for
the amino acid residues which are involved in bond formation
(ILE54, ARG57, GLU59, ARG104, ASP174 and ARG224) and spa-
tially nearby residues in the binding site decreased after dock-
ing when compared with that before docking. The decrease in
SASA values confirms that these amino acid residues are
involved in the bond formation with the ligand molecules.
ADME properties
The ADME properties for the new ligands identified namely
M1 to M6 are calculated and tabulated in Table 2. These mole-
cules have properties within the limits projected as per the
Lipinski rules of 5 and Jorgensen’s rules of 3, with medium
human oral absorption, which signifies that the ligand
molecules have acceptable ADME properties.
Conclusion
The virtual screening studies performed using Sigma lifechem
database against active site residues of SigF reveal ILE54,
ARG57, GLU59, ARG104, ASP174 and ARG224 amino acid resi-
dues to be important for binding in the SigF protein. A sample
of six ligands is presented in the present communication; sev-
eral novel scaffolds are identified in the virtual screening stud-
ies. The piperazine-l-yl acetic acid moiety and an amide group
in the ligands commonly exist and forms hydrogen bonds with
ARG104 and ARG224 of the SigF protein. The ligand molecules
show admissible ADME properties and are identified as novel
antagonists for the SigF protein. Further work is in progress
in the direction of identifying novel potent inhibitors for the
SigF protein, which is important for virulence.
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